Biotech Daily

Tuesday July 28, 2026

Daily news on ASX-listed biotechnology companies

*** ASX UP, BIOTECH DOWN: EBR UP 18%; ARTRYA DOWN 9%**

*** SOMNOMED UNAUDITED REVENUE UP 3% TO $114-115m**

*** CORRECTION: BOTANIX RECEIPTS UP 759% TO $46.2m**

*** IMPEDIMED RECEIPTS UP 6% TO $15m**

*** MICROBA SHARE PLAN RAISES $408k; $592k SHORTFALL; TOTAL $5.4m**

*** CLINUVEL PHASE III SCENESSE VITILIGO RESULTS 'THIS YEAR'**

*** DORSAVI DEVELOPS A.I. WEARABLE SENSOR**

*** AMPLIA 150% DIRECTOR FEE HIKE, 2.8m BOARD OPTIONS AGM**

*** SOMNOMED LOSES CO-CEO AMRITA BLICKSTEAD; KAREN BORG CEO**

*** AIKENHEAD APPOINTS MICHELLE GOLDSMITH CEO**

*** AROA APPOINTS MICHAEL LYNSKEY CCO, MIKE FALCON US G-M**

*** KAMILLE DIETRICH REPLACES IMEX CO SEC REENA MINHAS**

MARKET REPORT
The Australian stock market was up 0.6 percent on Tuesday July 28, 2026, with the ASX200 up 53.8 points to 8,947.8 points. Eleven of the Biotech Daily Top 40 companies were up, 19 fell and 10 traded unchanged. All four Big Caps were up.

EBR was the best, up 4.5 cents or 18.4 percent to 29 cents, with 7.6 million shares traded. Resonance and Starpharma were up more than seven percent; Avita, Cochlear and Polynovo climbed more than four percent; Resmed was up 3.4 percent; Alcidion, CSL, Dimerix, Nanosonics and Neuren rose two percent or more; Saluda and Telix were up more than one percent; with Pro Medicus up by 0.55 percent.

Artrya led the falls, down 53 cents or 9.4 percent to $5.09, with 600,042 shares traded. Nova Eye lost 7.7 percent; Medical Developments was down 6.25 percent; Aroa shed 5.2 percent; Clarity, Imugene and Prescient fell more than four percent; Cyclopharm, Emvision, Mesoblast, Micro-X, Optiscan and Proteomics were down more than three percent; Actinogen, Immutep, Imricor and Paradigm shed more than two percent; Racura was down 1.45 percent; with 4D Medical down by 0.9 percent.

SOMNOMED

Somnomed says unaudited revenue for the year to June 30, 2026 is expected to rise 2.7 percent to $114 million to $115 million, compared to the prior corresponding period.

Last year, Somnomed said that the revenue for the year to June 30, 2025 from sales of its Somnodent products for obstructive sleep apnoea, snoring, bruxism and other sleep-related breathing disorders was up 21.6 percent to $111,492,941, with its net loss after tax down 71.8 percent to $3,456,329 (BD: Aug 28, 2025).

Today, the company said that it expected earnings before interest, taxation, depreciation and amortization (Ebitda) to be in the middle of the guidance range of $10 million to $12 million and that “the lower top-line growth reflects a change in market dynamics in Europe in [the six months to June 30, 2026] and the impact from the appreciation of the Australian dollar”.

Somnomed said it “saw a change to public reimbursement rules and clinical eligibility criteria in some European markets”.

“Together with a shift in patient referral pathways between sleep clinics and dental and community providers, this led to a slowing of the pace at which eligible patients reach oral appliance therapies,” the company said.

Somnomed said during the year it began a controlled market release of its Virtus obstructive sleep apnoea and co-existing sleep bruxism therapy for patients in North America, Europe, and Asia Pacific.

The company said it expected high single-digit revenue growth in the year to June 30, 2027, while maintaining Ebitda margins consistent with the year to June 30, 2026.

Somonomed said that it had cash of $17.2 million at June 30, 2026 compared to $17.3 million at June 30, 2025.

Somnomed was unchanged at 47 cents with one million shares traded.

CORRECTION: BOTANIX PHARMACEUTICALS

Last night’s edition incorrectly reported Botanix receipts from customers for the year to June 30, 2026 were up 11.3 percent to $1,348,000 million, compared to the prior year.

Botanix has told Biotech Daily that figure referred to legacy royalties alone, and that the sales of its Sofdra or sofpironium bromide, for excessive sweating, as well as the royalties were up 759.4 percent to a total of $46,177,000 compared to $5,373,000 in the year to June 30, 2025.

The company said customer receipts for the three months to June 30, 2026 were up 237.6 percent to $13,609,000 compared to the previous corresponding period.

In 2024, Botanix said that the US Food and Drug Administration had approved Sofdra for excessive underarm sweating in adults and children aged nine years and older (BD: Jun 20, 2024).

Yesterday’s announcement included a $19,638,000 deduction for “payments for gross to net deductions from product sales” and in the covering letter, the company said that “Sofdra net revenue (unaudited) increased 45 percent for the quarter from $6.9 million in [the three months to March 31, 2026] to $10.1 million in [the three months to June 30, 2026] on gross sales of $46.7 million [for the three months to June 30, 2026]”.

The company said it had a cash burn of $10,620,000 for the three months to June 30, 2026, with cash and cash equivalents of $36,631,000 at June 30, 2026 compared to $64,888,000 at June 30, 2025.

The error was made by the Monday Appendix 4C quarterly reports sub-editor who failed to read the notice correctly and has been summarily dismissed.

Botanix was unchanged at 2.1 cents with 16 million shares traded.

IMPEDIMED

Impedimed says receipts for the year to June 30, 2026 was up 5.7 percent to $14,771,000, compared to the previous corresponding period.
Impedimed said receipts for the three months to June 30, 2026 from sales of its Sozo bioimpedance spectroscopy for lymphoedema, heart failure and malnutrition rose 13.0 percent to $4,275,000, compared to the prior corresponding period.
The company said it expected business annual recurring revenue to be $14.4 million for the year to June 30, 2027, “impacted by a relatively stronger Australian dollar”.
Impedimed said it had a $4,949,000 three-month cash burn, with cash and cash equivalents of $15,286,000 at June 30, 2026 compared to $22,248,000 at June 30, 2025.
Impedimed was unchanged at 0.4 cents with 18.3 million shares traded.

MICROBA LIFE SCIENCES

Microba says it has raised $407,500 at five cents a share in a share purchase plan, leaving a $592,500 shortfall and taking the total raised to $5,407,500.
Last month, Microba said it placed $5.0 million at five cents a share, with a $1.0 million share purchase plan to follow (BD: Jun 12, 2026).
Today, the company said investors would receive one option for every share issued, exercisable at 6.25 cents each, within three years of issue; and the funds would be used for its Australia and UK diagnostics and, the delivery of an additional testing product.
The company did not disclose whether it would raise the shortfall.
Microba was up 0.2 cents or 4.35 percent to 4.8 cents.

CLINUVEL PHARMACEUTICALS

Clinuvel says it expects results from its 210-patient, “late-stage” study trial of Scenesse with adjuvant narrowband ultra-violet B photo-therapy for vitiligo “in December 2026”.
Last year, Clinuvel said it reached its 200-patient recruitment target in its phase III trial of Scenesse for vitiligo, with results expected by 2027 (BD: May 7, 2025).
Today, the company said the study would be followed by a pivotal, registrational study, expected to begin in November, with 300 vitiligo patients with darker skin types as agreed with the European Medicines Agency.
Clinuvel was unchanged at $9.81.

DORSAVI

Dorsavi says it has completed its first physical artificial intelligence (A.I.) wearable sensor for movement processing, with uses in healthcare, defence and sport.
Dorsavi said the version 6.5 ran on conventional silicon and used its remote random access memory (RRAM) and related technologies to push toward always-on operation.
Last year, the company said it would pay $1,320,000 for Nanyang Technological University’s RRAM to extend the battery life of wearable sensors (BD: Jun 12, 2025).
Today, Dorsavi said the sensor “performed analysis and decision-making on the sensor … removing the latency, bandwidth and power cost of sending data to the cloud and back”.
Dorsavi said the FDA and TGA cleared version 6.5 sensor assessed “movement quality on the device, distinguishing normal movement, elite performance characteristics and patterns associated with injury risk, and delivers configurable haptic, audible or visual biofeedback within milliseconds”.
Dorsavi was unchanged at 2.8 cents.

AMPLIA THERAPEUTICS

Amplia says investors will vote to increase the director fee pool by 150 percent and issue 2,830,629 zero exercise price options to its managing-director and board.
Amplia said its annual general meeting would vote to issue managing-director Dr Chris Burns 687,772 zero exercise price options, chair Jane bell 642,857 zero exercise price options and 500,000 zero exercise price options, each, to directors Dr Robert Peach, Dr Warwick Tong and Brett Carter.
The company said the options were in addition to Dr Burns' $350,000 a year salary, Ms Bell's $90,000 annual pay and Dr Peach, Dr Tong and Mr Carter's $70,000 fees, valued at equal to their directors' fees and exercisable within five years.
Amplia said the meeting would vote to increase the aggregate director fee pool by 150 percent from $300,000 a year to $750,000 a year.
The company said the meeting would vote to approve the remuneration report, re-elect directors Dr Robert Peach and Brett Carter and approve the 10 percent placement capacity.
Amplia was unchanged at 13 cents.

SOMNOMED

Somnomed says Amrita Blickstead will step down as joint chief executive officer, effective from yesterday, with Karen Borg to continue as chief executive officer.
Somnomed said Ms Blickstead's contribution "was significant, particularly in improving overall financial performance and customer satisfaction through faster product turnaround times and substantial capacity increases at the manufacturing facility'.
In 2024, the company said it appointed Ms Blickstead and Ms Borg as joint chief executive officers, replacing Neil Verdal-Austin (BD: Feb 23, 2024).
Today, Somnomed said it had promoted chief transformation officer Greg Knight to chief operating officer to manage manufacturing, regulatory affairs and quality assurance, research and development as well as strategy.

AIKENHEAD CENTRE FOR MEDICAL DISCOVERY

The Aikenhead Centre for Medical Discovery says it has appointed Michelle Goldsmith as its chief executive officer, effective from "early December 2026".
Melbourne's Aikenhead Centre said that Ms Goldsmith was appointed "following a highly competitive national recruitment process".
The Centre said Ms Goldsmith had been chief executive officer of Agriculture Victoria Services since 2023, had more than 20 years of experience in scientific commercialization and had previously worked for Strategic Project Partners, the Florey Institute and Global Kinetics.
The Aikenhead Centre said Michael Krieg would continue as interim chief executive officer until Ms Goldsmith commenced the role.
In 2022, the Victoria Government said construction was approved at the $206 million Aikenhead Centre for Medical Discovery at Melbourne's St Vincent's Hospital, and that it would contribute $60 million to the project (BD: Apr 11, 2022).
In 2024, the State Government said that the structural construction for the Aikenhead Centre for Medical Discovery at St Vincent's Hospital in Fitzroy had been completed (BD: Aug 5, 2024).

AROA BIOSURGERY

Aroa says it has appointed Michael Lynskey as chief commercial officer and Mike Falcon as US general manager.

Aroa said Mr Lynskey had more than 20 years of experience in wound healing sales and had worked for Smith + Nephew, Stryker and Johnson & Johnson.

According to his Linkedin page, Mr Lynskey held a Bachelor of Arts from England's Leeds Beckett University.

The company said Mr Falcon had worked at Lifenet Health and had previously held leadership positions with Biomet and Johnson & Johnson.

According to his Linkedin profile, Mr Falcon held a Bachelor of Arts from Oxford's University of Mississippi and a Master of Business Administration from North Carolina's Queens University of Charlotte.

Aroa said the appointments added "seasoned leadership capability to support continued momentum across the Myriad product portfolio, and to capitalize on the recent market reset that has increased the opportunity for Aroa's outpatient product, Symphony".

Aroa fell three cents or 5.2 percent to 55 cents.

IMEX HEALTH SERVICES

Imex says Reena Minhas has resigned as company secretary, effective immediately, with Automic Group's Kamille Dietrich appointed as company secretary.

Imex fell 2.5 cents or 8.2 percent to 28 cents.